In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK/Actelion: Phase III Value Is in the Eye of the Beholder

Executive Summary

GSK paid a very large upfront fee ($148mm) for access to Actelion's Phase III insomnia candidate almorexant, but still some were disappointed; the Big Pharma is only paying 40% of the costs of the Phase III program. The truth is that even late-stage primary care assets--especially those with novel mechanisms of action--are under intense regulatory scrutiny and licensors are having to take on more risk.
Advertisement
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel